Home > News > Industry > Pharma News > Torrent Pharma, Eli Lilly...

Torrent Pharma, Eli Lilly ink pact to boost Baricitinib production in India

By - Ruchika Sharma
Published On 2021-05-14 09:53 GMT   |   Update On 2021-05-14 09:53 GMT

Ahmedabad: Following in the footsteps of Sun Pharma, Cipla, and Lupin in signing a voluntary licencing agreement with Eli Lilly to accelerate the production of Baricitinib for the treatment of COVID-19 patients in India, now Torrent Pharmaceuticals has signed a royalty free, non-exclusive voluntary licencing agreement with Eli Lilly to boost the production of Baricitinib.Under the...

Login or Register to read the full article
Register Now

Ahmedabad: Following in the footsteps of Sun Pharma, Cipla, and Lupin in signing a voluntary licencing agreement with Eli Lilly to accelerate the production of Baricitinib for the treatment of COVID-19 patients in India, now Torrent Pharmaceuticals has signed a royalty free, non-exclusive voluntary licencing agreement with Eli Lilly to boost the production of Baricitinib.

Under the agreement, Lilly has provided the license to manufacture and distribute baricitinib to Torrent for India along with Lilly's other license partners.

The agreement will help ensure wider reach and access to patients in India and further adds to Torrent Pharma's effort in helping patients affected by the pandemic. Baricitinib has been approved by the Central Drug Standard Control Organisation (CDSCO), India for restricted emergency use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.
Commenting on the agreement, Aman Mehta, Chief Marketing Officer for Torrent said, "We are pleased to partner and work closely with Lilly to bring this treatment to market. This partnership further strengthens our efforts to help the nation fight the pandemic and provide quality treatment to patients. Torrent Group stands firmly committed to support the nation during this time of crisis."

Read also: Eli Lilly ink licensing pact with Sun Pharma, Cipla, Lupin to expedite COVID drug Baricitinib




Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Conduct bridging CT, prove efficacy, safety: CDSCO Panel Tells Glenmark on Roflumilast Cream of additional strength, indication
Glenmark Pharma gets USFDA nod for Acetaminophen and Ibuprofen Tablets
Diabetes drug: Sanofi unveils Soliqua in India
14 products of Baba Ramdev suspended by Indian State regulator: Report
Pfizer-Genmab gets full USFDA approval for Tivdak to treat recurrent or metastatic cervical cancer
Granules India arm gets USFDA nod for Gout flares drug Colchicine
AstraZeneca Gets CDCSO Panel Nod to Import, market Eculizumab to treat Paroxysmal Nocturnal Hemoglobinuria
Gland Pharma appoints Satnam Singh Loomba as COO, Senior Management Personnel